All NewsEducationTV
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Eli Lilly raises annual revenue forecast on strong drug demand

Created at 5 Aug · 11:08 AM1 source↑ Market-relevant
IN SHORT

Eli Lilly and Co has increased its full-year revenue forecast, citing sustained demand for its obesity and diabetes drugs. The company now expects revenue between $85 billion and $87 billion, up from its previous projection of $82 billion to $85 billion.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

$85 billion to $87 billionEli Lilly's updated full-year revenue forecast
$82 billion to $85 billionEli Lilly's previous full-year revenue forecast

Who's Involved

Eli Lilly and Co
raised full-year revenue forecast due to strong drug demand
Novo Nordisk
rival that also hiked its full-year profit and sales forecast
Eli Lilly raises annual revenue forecast on strong drug demand

↳ Why This Matters

Eli Lilly's increased revenue forecast signals continued strong market performance for its key obesity and diabetes medications, indicating robust consumer demand and a positive outlook for the company's financial performance in the coming year.

Key facts

  • Eli Lilly raised its full-year revenue forecast.
  • The company now expects revenue between $85 billion and $87 billion.
  • The previous forecast was $82 billion to $85 billion.
  • Demand for its obesity and diabetes drugs remains strong.

Eli Lilly and Co raised its full-year revenue forecast on Wednesday, driven by sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs. The company now anticipates revenue between $85 billion and $87 billion, an increase from its prior projection of $82 billion to $85 billion. This upward revision follows a similar move by rival Novo Nordisk, which also hiked its full-year profit and sales forecast, aiming to regain market share in the lucrative obesity sector with its oral Wegovy pill.

Frequently asked questions

Eli Lilly now expects revenue between $85 billion and $87 billion for the full year.

The sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs is driving the increased forecast.

The previous forecast was between $82 billion and $85 billion.

Novo Nordisk also recently hiked its full-year profit and sales forecast.

What Happens Next

01Eli Lilly will continue to monitor demand for its GLP-1 drugs.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • S&P 500 futures hit new highs as tech sector rallied on strong earnings.
    4 Aug · 8:23 PM
  • S&P 500 futures hit new highs as tech sector rallied on strong earnings.
    4 Aug · 8:23 PM
  • Initial Listing of the E-nano Standard and Poor’s 500 Stock Price Index Futures, E-nano Nasdaq-100 Index Futures, E-nano Russell 2000 Index Futures and E-nano Dow Jones Industrial Average Index Futures Contracts
    4 Aug · 6:45 PM

How It Developed

Eli Lilly raised its full-year revenue forecast.
The company now expects revenue of $85 billion to $87 billion, up from $82 billion to $85 billion.

Sources

T1
Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strongReuters
T2
Eli Lilly (LLY) earnings Q2 2026 - CNBCcnbc.com

Related Stories

CVS Health raises annual profit forecast on improved drug revenues
4 Aug · 4:46 PM
Kraft Heinz lowers annual sales and profit forecasts
5 Aug · 11:16 AM
Amgen, Gilead report strong sales growth, beat estimates
4 Aug · 8:06 PM
Leidos raises annual forecasts on strong defense demand
4 Aug · 3:36 PM
Thomson Reuters reports higher second-quarter revenue
5 Aug · 10:56 AM